Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 1 1

Status

Completed 6Recruiting 5Terminated 4Active not recruiting 2Not yet recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 2

Conditions

Primary Myelofibrosis 9Myeloproliferative Disorders 5Polycythemia Vera 4Thrombocythemia, Essential 3Neoplasms 3Leukemia, Myeloid, Acute 3Leukemia 3Recurrence 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Myelodysplastic Syndromes 2Lymphoma, Non-Hodgkin 2Leukemia, Myelomonocytic, Chronic 2Leukemia, Myeloid, Chronic-Phase 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Breast Neoplasms 2Uveal Melanoma 1Triple Negative Breast Neoplasms 1Thalassemia 1Pancreatic Neoplasms 1Other Cancer 1Mesothelioma 1Melanoma 1Lymphoma, Follicular 1Lymphoma 1Lung Neoplasms 1Leukemia, Lymphocytic, Chronic, B-Cell 1Inflammatory Breast Neoplasms 1Hypereosinophilic Syndrome 1Graft vs Host Disease 1Exanthema 1

Interventions

Cyclophosphamide 35fludarabine 18Methotrexate 17fludarabine phosphate 16Dexamethasone 16blinatumomab 15Vincristine 15Cytarabine 14Melphalan 12Tacrolimus 11Etoposide 11pegaspargase 10Whole-Body Irradiation 9Mercaptopurine 9Calcium Dobesilate 9merphos 8Dasatinib 8Busulfan 8Asparaginase 8Thiotepa 7Prednisone 7Mycophenolic Acid 7Leucovorin 7Granulocyte Colony-Stimulating Factor 7Doxorubicin 7prednylidene 6ponatinib 6calaspargase pegol 6Stem Cell Transplantation 6Specimen Handling 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × Precursor Cell Lymphoblastic Leukemia-Lymphoma × ruxolitinib × Clear all
NCT03117751 2025-12-05

Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma

St. Jude Children's Research Hospital

Phase 2/3 Active not recruiting
790 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02494882 2025-07-02

Adding Ruxolitinib to a Combination of Dasatinib Plus Dexamethasone in Remission Induction Therapy in Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Patients Aged 40 Years or Older

Memorial Sloan Kettering Cancer Center

Phase 1 Active not recruiting
12 enrolled
LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡